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Abstract
Background: In the periphery, C5a acts through the G-protein coupled receptor CD88 to
enhance/maintain inflammatory responses. In the brain, CD88 can be expressed on astrocytes,
microglia and neurons. Previous studies have shown that the hippocampal CA3 region displays
CD88-immunolabelling, and CD88 mRNA is present within dentate gyrus granule cells. As granule
cells send dense axonal projections (mossy fibres) to CA3 pyramidal neurons, CD88 expression
could be expressed on mossy fibres. However, the cellular location of CD88 within the
hippocampal CA3 region is unknown.
Methods: The expression of CD88 within the hippocampal CA3 region was characterized using
dual-immunolabelling of hippocampal sections prepared from Wistar rats. Immunolabelling for
CD88, using a monoclonal antibody, was combined with immunolabelling for markers of astrocytes
(GFAP), microglia (IBA1), presynaptic proteins (synaptophysin and synapsin-1) and preterminal
axons (neurofilament). In addition, electron microscopy was performed on peroxidase-visualized
CD88-immunolabelling to determine its cellular localisation within the CA3 region.
Results: Dense CD88-immunolabelling was observed within the stratum lucidum of the CA3,
consistent with the presence of CD88 on mossy fibres. Labelling for CD88 rarely co-localized with
astrocytes or microglia, but was highly co-localized with presynaptic proteins. Electron microscopy
revealed CD88-immunolabelling was localized to large presynaptic terminals within the stratum
lucidum.
Conclusion: These results demonstrate that CD88 is expressed on presynaptic terminals of
mossy fibres within the CA3 region of the hippocampus. Although the role of CD88 on mossy
fibres remains to be established, their involvement in synaptic/cellular plasticity, and in cognitive
disorders such as Alzheimer's disease deserves investigation.
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Background
The complement system is an integral part of the innate
immune system activated in response to tissue injury and
invading pathogens [1]. Consisting of over thirty fluid-
phase and membrane-associated proteins, a major func-
tion of the complement systems is cytotoxic destruction of
invading pathogens, via the formation of the membrane
attack complex [2,3]. However, due to the release of solu-
ble anaphylatoxins such as C3a and C5a, the complement
system also initiates and maintains inflammatory
responses [1]. For many years the complement system was
thought confined to the periphery, it is now recognised
that complement factors are expressed in the CNS [2,4,5].
Furthermore, the complement system has been impli-
cated in a number of neurodegenerative disorders, such as
Alzheimer's disease, Huntington's disease and amyo-
trophic lateral sclerosis [2,4,6-10].
The anaphylatoxin C5a, a 74 amino acid glycoprotein,
functions primarily as a pro-inflammatory mediator [3,4].
In the periphery, the release of C5a results in a host of
inflammatory responses, including increased vascular per-
meability, chemotaxis of inflammatory cells, and the
release of cytokines and chemokines [11]. These
responses are primarily mediated via a C5a-selective
seven-transmembrane G-protein coupled receptor
(termed CD88) [12]. This C5a-receptor is expressed on a
wide range of peripheral cells, including neutrophils,
monocytes, activated mast cells, endothelial cells, and vas-
cular smooth muscle cells [12]. In the CNS, CD88 can be
found on astrocyctes, microglia and neurons in normal
human and mouse brains [10,13-19]. Neuronal expres-
sion of CD88 has been reported within the cornus ammonis
sub-fields (CA1 - 3) of the hippocampus, the dentate
gyrus, the neocortex, and the cerebellum [18]. Similarly,
in situ hybridization has demonstrated CD88 mRNA
within neurons of the neocortex, cerebellum and dentate
gyrus [18].
Granule cells of the dentate gyrus send axonal projections
(the mossy fibres) that terminate on CA3 pyramidal neu-
rons within the stratum lucidum, a layer lying immediately
dorsal to CA3 pyramidal neurons [20]. These strong, exci-
tatory synapses formed by mossy fibres on CA3 pyramidal
neurons are critical for the normal function of the hippoc-
ampus, and dysfunction of this synapse is thought to con-
tribute to psychiatric disorders such as depression and
schizophrenia [20,21]. Although CD88 expression has
been reported in the CA3, its precise cellular location has
not been fully characterised. The presence of CD88 mRNA
within dentate gyrus granule cells [18] suggests CD88
might be expressed on mossy fibres within the CA3
region. Indeed, upon close examination of previous
reports [18], CD88 immunolabelling within the human
hippocampus does appear to be located within the stratum
lucidum. Determining whether CD88 is located presynap-
tically on mossy fibres, or postsynaptically on CA3 pyram-
idal neurons, is critical to our understanding of its
function in this region. Therefore, the present study
sought to characterize CD88 expression within the CA3
region of the rat hippocampus with the use of dual-immu-
nolabelling and electron microscopy.
Methods
Experimental animals
All results were obtained from male Wistar rats (postnatal
days 30-37) housed under standard laboratory conditions
with a 12-hour light/dark cycle and food and water avail-
able ad libitum. All procedures were carried out in accord-
ance with protocols approved by the University of
Queensland Animal Ethics Committee.
Western Blotting
Hippocampal homogenates were separated on a 10%
sodium dodecyl sulphate polyacrylamide gel and electro-
transferred to a nitrocellulose membrane (Pall). Mem-
branes were blocked for one hour at room temperature in
5% bovine-serum-albumin (BSA) in tris-buffered saline-
Tween 20 (TBS-T) prior to incubation with a monoclonal
mouse anti- rat CD88 antibody (1:1000; clone R63,
Hycult Biotechnology, Netherlands) overnight at 4°C.
Membranes were washed (3 × 10 min) in TBS-T before
being incubated for one hour at room temperature with
goat anti-mouse horseradish peroxidase secondary anti-
body (1:10000; GE Healthcare, USA). Immunoblots were
visualized by ECL chemiluminescence (GE Healthcare).
Fluorescence Immunohistochemistry
Animals (n = 8) were perfused trans-cardially with 2%
sodium nitrite solution (in 0.1 M phosphate-buffer, pH
7.4) followed by 100 ml of 4% formaldehyde (in 0.1 M
phosphate-buffer, pH 7.4). All brains were then removed
and postfixed overnight in 4% formaldehyde at 4°C, fol-
lowed by cryoprotection in 20% sucrose (in 0.1 M phos-
phate-buffered saline, pH 7.4) overnight at 4°C. Some
brains (n = 4) were infiltrated in a 1:1 solution of sucrose
and cryo-protectant medium (OCT Tissue-Tek, USA) over-
night. They were then embedded in 100% OCT, snap fro-
zen in liquid nitrogen and stored at minus 20°C prior to
the preparation of coronal sections (16 μm, Leica
CM1850 cryostat, Germany). For the remaining brains (n
= 2), coronal sections (50 μm) were prepared on a freez-
ing sliding-microtome (Leica SM 2000R, Germany).
All sections were washed in 0.1% phosphate-buffered
saline (PBS) and blocked in PBS containing 3% bovine
serum albumin (BSA, Sigma-Aldrich, MO, USA). Sections
were then incubated in a monoclonal mouse anti-CD88
antibody (1:500 in PBS containing 1% BSA, 4°C; Clone
R63, Hycult Biotechnology) for 48 hours, after which theyJournal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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were washed in PBS and incubated overnight at 4°C in a
solution of biotinylated donkey anti-mouse antibody
(1:300 in PBS containing 1% BSA; Jackson ImmunoRe-
search, USA). After washing in PBS, sections were incu-
bated in one of the following primary antibodies (made
up in PBS containing 1% BSA). Microglia were labelled
with a rabbit anti-ionizing calcium-binding molecule
antibody (IBA1, 1:600, Biocare Medical, USA). Astrocytes
were labelled with a rabbit anti-glial fabrillary acidic pro-
tein antibody (GFAP, 1:100; DAKO, Denmark). Presynap-
tic terminals were labelled using two antibodies directed
against protein components of the presynaptic vesicular-
release machinery: rabbit anti-synaptophysin antibody
(1:100, DAKO), or rabbit anti-synapsin-1 antibody
(1:100, Sigma-Aldrich). Preterminal portions of axons
were labelled with neurofilament-200 kDa antibody
(1:500, Sigma-Aldrich). Following an overnight incuba-
tion at 4°C, all sections were washed thoroughly in PBS
and incubated in a mixture of Alexa 568-conjugated
streptavidin (1:300 in PBS containing 1% BSA, Invitrogen,
CA, USA) and Alexa 488-conjugated goat anti-rabbit anti-
body (1:300 in PBS containing 1% BSA, Invitrogen). Fol-
lowing a wash in PBS, 16 μm thick sections were
incubated for 5 min in 4, 6-diamidino-2-phenylindole
(DAPI, 1:15000) and then washed with PBS. All sections
were cover-slipped in fluorescence mounting medium
(DAKO, Denmark), sealed with acrylic and stored at 4°C.
Images were acquired using an Axio Imager 319 micro-
scope equipped with a Zeiss AxioCam MRm camera.
Immunohistochemistry - electron microscopy
Animals (n = 2) were perfused transcardially with 2%
sodium nitrite solution (in 0.1 M phosphate buffer, pH
7.4) followed by 50 ml of 4% formaldehyde containing
0.5% glutaraldehyde (in 0.1 M phosphate buffer, pH 7.4).
Brains were then removed and postfixed overnight in the
same fixative at 4°C and then washed in PBS, after which
coronal forebrain (50 μm) sections were cut using a
vibratome (Leica VT1000S). All sections were washed (4 ×
10 min) in PBS, incubated in a 3% BSA/PBS solution and
then incubated in mouse anti-CD88 antibody (1:500 in
PBS containing 1% BSA, 4°C; Hycult Biotechnology) for
48 hours. Sections were then washed in PBS and incu-
bated for 2 hours in a solution of biotinylated donkey
anti-mouse antibody (1:300 in PBS containing 1% BSA.
Jackson ImmunoResearch). After further PBS washes sec-
tions were placed into a solution of avidin-biotin-horse-
radish peroxidase complex (6 μl A and 6 μl B/ml of 1%
BSA in PBS; Vector Elite ABC kit, Vector Laboratories,
USA) for 2 hours. This was followed by PBS washes (2 × 5
min) and a sodium acetate buffer (pH = 6.0) wash for 5
min. Sections were exposed for 15 min to a 2% NiSO4
solution (in sodium acetate buffer) containing 2 mg/ml
D-glucose, 0.4 mg/ml NH4Cl and 0.025% 3,3-diami-
nobenzidine (DAB). This was followed by another incu-
bation in the same solution but with the addition of
glucose oxidase (0.2 μl/ml). The subsequent production
of H2O2 initiates the peroxidase reaction resulting in the
deposition of nickel-DAB. At a suitable time point, based
on the background level of staining seen, all sections were
washed in sodium acetate buffer to stop the reaction, and
then washed thoroughly in PBS (3 × 10 min). Sections
were then stained in 1% osmium tetroxide, dehydrated
through a graded series of acetone, and processed into
epon resin using a microwave (Pelco Biowave). Sections
were flat embedded in resin which was polymerized at
60°C for 48 hr. Ultrathin sections (70 nm thick) were cut
using an ultra-microtome (Lecia EMUC6) and collected
onto grids, stained with uranyl acetate and lead citrate,
and examined with a JEOL 1010 electron microscope.
Results
CD88 is expressed within the stratum lucidum of the 
hippocampus
To confirm previous reports that CD88 is expressed
within the rat hippocampus [18], western blots were per-
formed. These blots revealed a single band at 45 kDa, the
predicted size of glycosylated CD88. A similar band was
also observed in lanes containing peripheral blood mono-
nuclear cells; a population of cells known to express cell
surface CD88 (Figure 1A).
We next performed immunolabelling for CD88 to deter-
mine the location of these receptors within the rat hippoc-
ampus. In contrast to sections immunolabelled without
the inclusion of the primary antibody (Figure 1B), strong
immunolabelling for CD88 was observed within the stra-
tum lucidum of the CA3 region. This labelling was seen in
every animal and extended across the entire rostrocaudal
extent of the CA3 region (Figure 1C and 1D).
CD88 expression is rarely co-localized with astrocytes and 
microglia
CD88 can be expressed by astrocytes, microglia and neu-
rons [4,5]. To determine whether the CD88 in the stratum
lucidum was located on astrocytes or microglia we per-
formed dual immunolabelling for CD88 and either GFAP
(a marker of astrocytes) or IBA1 (a marker of micoglia)
(Figure 2A-L). Astrocytes were found within the stratum
lucidum  (Figure 2B and 2E). However, while astrocytes
expressed CD88, the vast majority of CD88 labelling
within the stratum lucidum was not co-localized with astro-
cytes (Figure 2C and 2F). Similarly, although microglia
were present within the stratum lucidum (Figure 2H and
2K) and expressed CD88, the vast majority of CD88 label-
ling within the stratum lucidum was not co-localized with
microglia (Figure 2I and 2L).
CD88 in the stratum lucidum co-localizes with 
presynaptic markers
The above results indicate that CD88 within the stratum
lucidum is located on neuronal membranes. The stratumJournal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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CD88 expression within the hippocampal stratum lucidum Figure 1
CD88 expression within the hippocampal stratum lucidum. (A) Western blot demonstrating the presence of CD88 
protein within the rat hippocampus (Hip). A single band was observed at 45 kDa. A similar immuno-reactive band was found in 
peripheral blood mononuclear cells (PBMC) that are known to express CD88. (B) Control section immunolabelled without 
mouse anti-ratCD88 antibody. No labelling was present within the stratum lucidum in these sections. (C and D) Intense immu-
nolabelling for CD88 was observed within the stratum lucidum (St. Luc.) of the hippocampus (red). This immunolabelling was 
seen throughout the rostrocaudal extent of the hippocampus: (C) rostral hippocampus, (D) caudal hippocampus. Blue labelling 
in all sections is DAPI-stained nuclei. CA3, cornu ammonis 3; DG, dentate gyrus; St. Luc., stratum lucidum. Scale bar = 200 μm.Journal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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CD88 in the stratum lucidum rarely co-localised with astrocytes and microglia Figure 2
CD88 in the stratum lucidum rarely co-localised with astrocytes and microglia. (A-F) Immunolabelling for CD88 
(red) in the stratum lucidum of the hippocampus rarely co-localised with immunolabelling for GFAP (a marker of astrocytes) 
(green). Although GFAP-positive cells expressed CD88, the vast majority of CD88 immunlabelling in the stratum lucidum did 
not co-localize with GFAP. (G-L) Immunolabelling for CD88 (red) in the stratum lucidum of the hippocampus rarely co-localised 
with immunolabelling for IBA1 (a marker of microglia) (green). Although IBA1-positive cells expressed CD88, the vast majority 
of CD88 immunolabelling in the stratum lucidum did not co-localize with IBA1. GFAP, glial fabrillary acidic protein; IBA-1, ioniz-
ing calcium-binding molecule. Scale bars = A-C, 200 μm; D-F, 20 μm; G-I, 200 μm; J-L, 20 μm.Journal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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lucidum contains a dense bundle of axons (termed the
'mossy fibres') that originate from the granule cells within
the dentate gyrus [20]. These axons form specialized syn-
aptic connections with proximal portions of the apical
dendrites of CA3 pyramidal neurons [20]. In the present
study, the pattern of CD88 immunolabelling seen within
the hippocampus (Figure 1C and 1D) was identical to that
seen when mossy fibres are visualised using a Timm's
stain [20]. As such, we sought to determine whether CD88
within the stratum lucidum was co-localised with two dif-
ferent components of the presynaptic-release machinery:
synaptophysin and synapsin-1 (Figure 3A-L).
As expected, there was a dense labelling for synaptophysin
within the stratum lucidum, consistent with its expression
within mossy fibre terminals (Figure 3B and 3E). In con-
trast to the results seen with GFAP and IBA1, CD88 label-
ling was almost entirely co-localized with synaptophysin
labelling (Figure 3A-F). A similar result was obtained from
dual immunolabelling for CD88 and synapsin-1 (Figure
3G-L). Dense labelling for synapsin-1 was observed
within the stratum lucidum (Figure 3H and 3K), and this
displayed a high degree of co-localization with immu-
nolabelling for CD88 (Figure 3G-L).
To further characterize the presynaptic location of CD88,
we co-immunolabelled sections for CD88 and neurofila-
ment-200 kDA (a marker of pre-terminal portions of
axons) [22] (Figure 3M-O). There was dense labelling for
neurofilament within the stratum lucidum (Figure 3N and
3O), consistent with the large bundle of axons present
within this region. However, the vast majority of labelling
for CD88 did not co-localize with neurofilament (Figure
3M-O).
Electron microscopy: CD88 is localized to presynaptic 
terminals
To further examine the subcellular localisation of CD88
within the stratum lucidum we examined nickel-DAB
intensified CD88 immunolabelling using electron micro-
scopy (Figure 4A-H). Using light microscopy, immunola-
belling for CD88 was seen as punctate nickel-DAB
deposits within the stratum lucidum (Figure 4A), consistent
with the labelling seen with immunoflourescent immu-
nohistochemistry (Figure 1C and 1D). Examination of a
adjacent sections using electron microscopy confirmed a
lack of CD88 immunolabelling within the pyramidal cell
layer of the CA3 region (Figure 4B). Similarly, nickel-DAB
deposits were absent from stratum lucidum sections that
were not immunolabelled for CD88 (Figure 4C). In con-
trast, in sections immunolabelled for CD88, electron-
dense nickel-DAB deposits were localised to large presyn-
aptic terminals in the stratum lucidum (Figure 4D-H).
These terminals were densely packed with presynaptic ves-
icles and were present in apposition to dendritic processes
(Figure 4D-F). Terminals immunolabelled for CD88 were
also seen opposite postsynaptic densities, a marker of
glutamatergic synapses (Figure 4G and 4H).
Discussion
The results presented here clearly demonstrate that the G-
protein coupled C5a-receptor (CD88) is located on presy-
naptic terminals of granule cell axons (mossy fibres)
located in the stratum lucidum of the CA3 region of the rat
hippocampus. Immunolabelling for CD88 revealed a pat-
tern of expression identical to that observed when mossy
fibres are visualized with a Timm's stain [20]. Consistent
with this, immunolabelling for CD88 almost entirely co-
localized with immunolabelling for the presynaptic pro-
teins synaptophysin and synapsin-1. However, CD88
immunolabelling rarely co-localized with neurofilament
(a marker of pre-terminal portions of the axon). The local-
isation of CD88 was further determined using electron
microscopy, demonstrating CD88 immunolabelling
within large presynaptic terminals of the stratum lucidum.
The production and specificity of the CD88 antibody used
in this study (monoclonal mouse anti-ratCD88, clone
R63) has previously been fully described [23]. Briefly, this
antibody was raised against membrane-expressed CD88
in a rat basophilic leukemia cell line (RBL-2H3). The spe-
cificity of the antibody raised was the established using
flow cytometry and ELISA procedures, with the antibody
found to target the N-terminal region (the putative first
extracellular domain) of CD88. In the present study, west-
ern blot analysis revealed that this CD88 antibody
detected a single 45 kDa band from both isolated hippoc-
ampus tissue and peripheral blood mononuclear cells.
Recently, a second C5a binding receptor has been identi-
fied termed C5a-like receptor 2 (C5L2) [24]. This receptor
does not appear to couple to G-proteins and is suggested
to be either a C5a decoy receptor [25,26] or a functional
C5a signalling receptor [27,28]. The C5L2 receptor and
CD88 display ~35% homology in their amino acid
sequences, and a considerable amount of this homology
is located in their N-terminal regions [12]. As the antibody
used in the present study binds in the N-terminal region
of CD88 we considered the possibility that this antibody
also recognized C5L2. To test this we immunolabelled rat
hippocampal sections with a specific anti-ratC5L2 anti-
body [29]. This revealed C5L2 expression on astrocytes,
but, consistent with previous reports [29], no C5L2
immunolabelling was observed on mossy fibres of the
stratum lucidum (data not shown). As such, the immunola-
belling seen within the stratum lucidum of the rat hippoc-
ampus in the present study is due to the presence CD88.
Immunolabelling for CD88 within the stratum lucidum of
the CA3 region of the hippocampus was found to display
a high degree of co-localisation with immunolabelling forJournal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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CD88 in the stratum lucidum co-localised with presynaptic proteins Figure 3
CD88 in the stratum lucidum co-localised with presynaptic proteins. (A-F) Immunolabelling for CD88 (red) in the stra-
tum lucidum displayed almost complete co-localization with the immunolabelling for the presynaptic protein synaptophysin 
(SNP)(green). There was a highly degree of co-localization of immunolabelling for CD88 and synaptophysin (yellow/orange) 
within the stratum lucidum of the hippocampus. (G-L) Immunolabelling for CD88 (red) in the stratum lucidum of the hippocam-
pus co-localized with immunolabelling for the presynaptic protein synapsin-1 (SYN) (green). There was a highly degree of co-
localization of immunolabelling for CD88 and SYN (yellow/orange) within the stratum lucidum of the hippocampus. (J-O) Immu-
nolabelling for CD88 (red) did not co-localize with immunolabelling for neurofilament (NF, a marker of preterminal portions of 
the axon) (green). Immunolabelling for NF within the stratum lucidum did not co-localize with immunolabelling for CD88. NF, 
neurofilament; SNP, synaptophysin; SYN, synapsin. Scale bars = A-C, 200 μm; D-F, 20 μm; G-I, 200 μm; J-L, 20 μm; M-O, 200 
μm.Journal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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CD88 is located on presynaptic terminals of the stratum lucidum Figure 4
CD88 is located on presynaptic terminals of the stratum lucidum. A) Low power photomicrograph of nickel-DAB vis-
ualized CD88 immunolabelling in the stratum lucidum (St. Luc.) of the rat hippocampus. Ultrathin sections from labelled stratum 
lucidum and the underlying pyramidal cell layer (Pyr) were further processed for electron microscopy. B) Electron micrograph 
taken through the pyramidal cell layer of the CA3 region. No nickel deposits were seen on pyramidal cells (P). C) Electron 
micrograph taken from unlabelled ultrathin sections from the stratum lucidum. Note the presence of unlabelled, large presynap-
tic terminals (te) in the stratum lucidum. D-H) Electron micrographs demonstrating nickel-DAB intensified labelling for CD88 
localized to presynaptic terminals of the rat stratum lucidum. D-F) Presynaptic terminals immunolabelled for CD88 (arrows) 
were located in close apposition to a dendritic process (d). G-H) Higher magnification electron micrographs of CD88 immu-
nolabelled presynaptic terminals demonstrating their close apposition to postsynaptic densities (arrow head). Scale bars = A, 
100 μm; B, 10 μm; C-H, 500 nm.Journal of Neuroinflammation 2009, 6:34 http://www.jneuroinflammation.com/content/6/1/34
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the presynaptic proteins synaptophysin and synapsin-1.
Both synaptophysin and synapsin-1 proteins are located
on synaptic vesicles and are involved in exocytosis of neu-
rotransmitter into the synaptic cleft [30,31]. As such, the
co-localization of CD88 immunolabelling with synapto-
physin and synapsin-1 immunolabelling indicates that
CD88 is located in close proximity to the presynaptic ter-
minals of mossy fibres within the stratum lucidum. In con-
trast, immunolabelling for CD88 was not co-localized
with neurofilament immunolabelling. As neurofilaments
are almost entirely confined to the preterminal region of
axons [22], this result indicates that CD88 expression is
confined to the presynaptic terminals of the mossy fibres.
This was subsequently confirmed using electron micros-
copy, in that CD88 immunolabelling was confined to
large presynaptic terminals present within the stratum luci-
dum.
The role of CD88 on mossy fibre terminals within the CA3
region of the hippocampus is not known. However, a
range of functions for CD88 within the CNS have been
proposed, including apoptosis, cytoskeletal plasticity and
axodendritic outgrowth, the migration of neural stem
cells, and the release of neurotrophins and cytokines [5].
Neuroblastoma cells respond to C5a with an increase in
calcium influx [32,33], increased expression of the imme-
diate early gene c-fos [32,33], activation of protein kinase-
C, and the nuclear translocation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) [18].
Activation of CD88 is mitogenic for undifferentiated neu-
roblastoma cells, protects terminally differentiated neu-
roblastoma cells against amyloid β peptide mediated
toxicity [18], and leads to calcium influx and apoptosis in
cortical neuronal cultures [14]. However, CD88 activation
also appears to protect against glutamate-mediated cell
death, possibly via the activation of the mitogen-activated
protein kinase cascade [34] and to have an anti-apoptotic
function in cultured cerebellar granule cells [13].
Primary neuronal cultures from the hippocampus
respond to CD88 activation with an increased calcium
influx [18]. Similarly, calcium influx into hippocampal
neurons is seen in brain slices treated with a CD88 agonist
[14]. Administration of C5a reduces kainic acid-induced
excitotoxicity in CA3 pyramidal neurons [35], and CA3
pyramidal neurons of CD88 knockout mice are more sus-
ceptible to excitotoxicity [36]. Interestingly, C5a has also
been suggested to act presynaptically to increase
noradrenaline release, a mechanism that might underlie
the increased eating seen in response to intra-hypotha-
lamic infusion of C5a [37,38]. Further, systemic adminis-
tration of a CD88 antagonist has been reported to
decrease the pathology, increase synaptophysin immu-
nolabelling in the CA3 stratum lucidum and enhance
behavioural outcomes in mouse models of Alzheimer's
disease [6]. These previous findings provide evidence that
C5a plays a neuromodulatory role in the CNS. That C5a
also acts through CD88 to modulate neurotransmission
between mossy fibres and CA3 pyramidal neurons is,
therefore, an intriguing possibility.
The generation of new neurons is thought to be a signifi-
cant form of plasticity within the CNS. Recently, cultured
neural stem cells have been shown to express CD88. This
expression was also found on doublecortin-positive cells
within the sub-ventricular zone (the primary site of neu-
rogenesis in the rodent brain) and rostral migratory
stream [39]. The subgranular zone of the hippocampal
dentate gyrus is a site of neurogenesis in the adult mam-
malian brain. Incorporation of these neurons into the
dentate gyrus and their subsequent synaptic connection to
CA3 pyramidal neurons appears to be involved in some
forms of hippocampal-dependent learning [21,40]. Given
that C5a acts as a strong chemotactic signal in the periph-
ery [1,11], it is possible that it also acts as a guidance cue
for the axons of newly formed granule cells.
Conclusion
The results of the present study clearly demonstrate that
CD88 expression within the CA3 region of the rat hippoc-
ampus is primarily located within the stratum lucidum of
the rat hippocampus. Immunolabelling for CD88 co-
localized with immunolabelling for the presynaptic pro-
teins synaptophysin and synapsin-1, suggesting that
CD88 is located on terminals of mossy fibre axons origi-
nating from dentate gyrus granule cells. This result was
confirmed using electron microscopy, demonstrating that
CD88 immunolabelling was confined to large presynaptic
terminals of the stratum lucidum. As such, the C5a-receptor
CD88 is well positioned to influence hippocampal func-
tion in both diseased and non-diseased states.
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